Results 28,081-28,100 of 51,305 for speaker:Micheál Martin
- Order of Business (31 May 2016)
Micheál Martin: Will the Taoiseach provide a list of those Bills?
- Order of Business (31 May 2016)
Micheál Martin: That is a very belated rationale for guillotines. It took five years to think that up.
- Order of Business (31 May 2016)
Micheál Martin: The Taoiseach is saying the list will be a re-list.
- Order of Business (31 May 2016)
Micheál Martin: We did not realise this for the past five years. We thought the Bills were coming.
- Order of Business (31 May 2016)
Micheál Martin: Next Wednesday?
- Leaders' Questions (31 May 2016)
Micheál Martin: That is no way to treat the Opposition.
- Leaders' Questions (31 May 2016)
Micheál Martin: That is exactly what is happening. Patients who are waiting for this medication cannot get it in hospitals. The clinicians are clear.
- Leaders' Questions (31 May 2016)
Micheál Martin: Any oncologist to whom I have spoken has been very clear about the efficacy of these drugs. The pharmacoeconomics unit which normally makes its determinations after weighing up cost-benefit analyses and survival rates made its decision in February. People were waiting for the HSE committee which was not due to meet until June to decide.
- Leaders' Questions (31 May 2016)
Micheál Martin: This is not the first time this has happened. There is a significant hiatus between the decisions of the pharmacoeconomics unit and those of the group of HSE officials. In no way is it good enough. What group of officials will second-guess the formal process of evaluation that has already taken place? Greece which is more fiscally challenged than Ireland has these drugs in operation and...
- Leaders' Questions (31 May 2016)
Micheál Martin: It can be.
- Leaders' Questions (31 May 2016)
Micheál Martin: I want to raise the unacceptable situation regarding the approval of life-saving drugs. This has come into the public domain again in the past week, in particular in the case of three drugs, namely, Pembro, Nivo and Ibrutinib. Pembro has had an astonishing impact in the treatment of melanomas and the prospects for its impact on lung and kidney cancer are also exciting, something to which...
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: Will he commission that report? Finally, regarding the arts, the Taoiseach had a very good engagement with the artistic community, as he articulated earlier. Did he at any time during his trip to the United States reflect on the absence of a real focus on the arts in Ireland? The artistic community feels very neglected, and the Taoiseach's attendance at and the strength of the event in...
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: I asked whether the Taoiseach would commission the report.
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: The implications.
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: We have a fair idea.
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: We are not in North Korea.
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: I am with the Taoiseach on that.
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: With regard to Donald Trump, the Taoiseach cannot predict who will win the next US presidential election and I accept this, but we can stand up for basic principles and we need to annunciate basic principles. What has been articulated in the US election is worrying. It is not acceptable for democrats to speak in the way Donald Trump has about various religions and ethnic groups and about...
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: Will we proceed with a one-to-one interaction?
- Ceisteanna - Questions: Taoiseach's Meetings and Engagements (31 May 2016)
Micheál Martin: It may be preferable to have the Taoiseach revert to me first.